P2X7 receptor: a potential therapeutic target for chronic respiratory diseases
Ping Huang1, Xichen Pang1, Xiaoju Liu2,3
1The First Clinical Medical College of Lanzhou University, Lanzhou, 730000, China.
Abstract:
The purinergic ligand-gated ion channel 7 receptor (P2X7R) is a non-selective ion channel activated by extracellular adenosine triphosphate. It promotes intracellular signal transduction by inducing Na+ and Ca2+ influx and K+ efflux. Moreover, this receptor is involved in the regulation of the inflammatory response, oxidative stress, cell death, and immune response. P2X7R is associated with the onset and progression of various chronic respiratory diseases, including asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, lung cancer, pulmonary arterial hypertension, and pulmonary tuberculosis. In this review, we comprehensively summarize the structure and functions of P2X7R as well as its roles and potential molecular mechanisms in chronic respiratory diseases. Additionally, we explored the application of P2X7R antagonists in clinical practice. In summary, targeting P2X7R may be a new strategy for treating chronic respiratory diseases, but we should still pay attention to its dual roles, especially in lung cancer.
Related Concept Videos
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...


